• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    2/23/24 4:31:07 PM ET
    $ATPC
    $BJDX
    $CELU
    $CPHI
    Medical/Nursing Services
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ATPC alert in real time by email

    Gainers

    • Ocean Biomedical (NASDAQ:OCEA) stock rose 37.6% to $2.16 during Friday's after-market session. The company's market cap stands at $73.6 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares rose 35.85% to $1.02. The market value of their outstanding shares is at $3.8 million.
    • ZyVersa Therapeutics (NASDAQ:ZVSA) shares moved upwards by 13.82% to $0.91. The company's market cap stands at $4.2 million.
    • Cadrenal Therapeutics (NASDAQ:CVKD) shares moved upwards by 11.9% to $0.7. The company's market cap stands at $9.1 million.
    • Virax Biolabs Group (NASDAQ:VRAX) stock increased by 10.63% to $0.98. The company's market cap stands at $2.3 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) stock increased by 8.95% to $0.81. The market value of their outstanding shares is at $1.4 million.

    Losers

    • Telesis Bio (NASDAQ:TBIO) stock decreased by 14.5% to $0.67 during Friday's after-market session. The company's market cap stands at $19.9 million.
    • Celularity (NASDAQ:CELU) stock fell 13.66% to $0.4. The market value of their outstanding shares is at $86.7 million.
    • Agape ATP (NASDAQ:ATPC) shares decreased by 6.36% to $0.33. The market value of their outstanding shares is at $25.5 million.
    • China Pharma Holding (AMEX:CPHI) shares decreased by 5.91% to $0.08. The company's market cap stands at $4.3 million.
    • Talphera (NASDAQ:TLPH) shares declined by 5.34% to $1.42. The market value of their outstanding shares is at $24.0 million.
    • Motus GI Hldgs (NASDAQ:MOTS) shares fell 5.02% to $0.75. The market value of their outstanding shares is at $1.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATPC
    $BJDX
    $CELU
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    Talphera Inc.
    $TLPH
    1/28/2025$4.00Buy
    Rodman & Renshaw
    Cadrenal Therapeutics Inc.
    $CVKD
    12/18/2023$4.00Outperform
    Noble Capital Markets
    Celularity Inc.
    $CELU
    1/30/2023$5.00 → $1.00Equal-Weight → Underweight
    Morgan Stanley
    Motus GI Holdings Inc.
    $MOTS
    1/25/2023Buy → Neutral
    Ladenburg Thalmann
    Celularity Inc.
    $CELU
    12/22/2022Outperform → Perform
    Oppenheimer
    Celularity Inc.
    $CELU
    6/22/2022$15.00Buy
    H.C. Wainwright
    Celularity Inc.
    $CELU
    4/6/2022$10.00Buy → Hold
    Truist
    More analyst ratings

    $ATPC
    $BJDX
    $CELU
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 12,738 shares and bought $85,587 worth of shares (105,364 units at $0.81), increasing direct ownership by 19% to 577,395 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:28:48 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 73% to 83,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:27:03 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Engineering Officer Dasu Badri N covered exercise/tax liability with 3,127 shares and bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 76% to 73,884 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:25:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BJDX
    $CELU
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Foster James Alexander Cunliffe

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/18/26 4:05:23 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Norton Evan Michael

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/18/26 4:05:19 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Davis Jason

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/18/26 4:05:13 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ATPC
    $BJDX
    $CELU
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026

    SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual investor and analyst event on Monday, March 23, 2026 at 11:00 AM ET featuring Blaithin McMahon, PhD, MBBChr (Medical University of South Carolina) and Joao Teixeira, MD (University of New Mexico), principal investigators in Talphera's NEPHRO CRRT study evaluating Niyad for continuous renal replacement therapy (CRRT). To register, click here.The experts will discuss their experience with CRRT, the anticoagulan

    3/18/26 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its

    3/12/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ATPC
    $BJDX
    $CELU
    $CPHI
    SEC Filings

    View All

    SEC Form 6-K filed by Virax Biolabs Group Limited

    6-K - Virax Biolabs Group Ltd (0001885827) (Filer)

    3/18/26 5:09:10 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/17/26 5:30:11 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Talphera Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - TALPHERA, INC. (0001427925) (Filer)

    3/16/26 8:30:44 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BJDX
    $CELU
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Virax Biolabs Group Ltd. with a new price target

    H.C. Wainwright initiated coverage of Virax Biolabs Group Ltd. with a rating of Buy and set a new price target of $3.00

    3/31/25 8:25:16 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Rodman & Renshaw initiated coverage on Talphera with a new price target

    Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00

    1/28/25 7:17:45 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Noble Capital Markets initiated coverage on Cadrenal Therapeutics with a new price target

    Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

    12/18/23 8:12:12 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BJDX
    $CELU
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATPC
    $BJDX
    $CELU
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    11/14/24 6:01:27 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Virax Biolabs Group Limited

    SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)

    11/14/24 4:46:07 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ATPC
    $BJDX
    $CELU
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

    Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr

    3/2/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

    ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases.The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS) with potential indication expansion in Alport syndrome and diabetic kidney disease.The lead indication for IC 100 is cardiometabolic conditions, with potential indication expansion in rare kidney diseases.Raised approximately $2.05 million in Q3-2025; $4.05 million year-to-date. WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- ZyVersa Th

    11/19/25 4:20:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care